MAPK3 and ductal breast carcinoma in situ: Accordingly, the TNFAIP3 and p-ERK1/2 protein levels were similar in DCIS-Ctrl cells treated with AP20187 or FGFR inhibitors, while the TNFAIP3 and p-ERK1/2 protein levels in DCIS-iFGFR1 cells were increased by AP20187 treatment and these increases were abolished by LY2874455 or AZD4547 treatment (Fig. 4b).